Physician profile
Jason Talbert
NPI 1972614659
$3,885.34
in general payments reported to CMS, 2019-2025
28 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $84.55 · 2021: $19.58 · 2022: $371 · 2023: $747 · 2024: $1,071 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $594.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $455.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $368.95 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $343.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $313.51 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $276.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $272.23 | 2022-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.66 | 2019-2025 | Jardiance, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $140.74 | 2019-2023 | Trintellix |
| Abbott Laboratories | $119.66 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $114.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $111.12 | 2019-2025 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $86.79 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $79.69 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $61.71 | 2023-2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.13 | 2019 | |
| Dexcom, INC. | $54.98 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $43.62 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $32.33 | 2024-2025 | Zenpep |
| Lundbeck LLC | $19.04 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.92 | 2022 | |
| Amarin Pharma, INC. | $14.86 | 2020 | |
| Circassia INC. | $14.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $14.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.88 | 2019 | |
| Allergan, INC. | $12.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Talbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.